Trial Profile
Expanded Access Program (EAP) to Provide Nusinersen to Patients With Infantile-onset Spinal Muscular Atrophy (SMA)
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Nusinersen (Primary)
- Indications Spinal muscular atrophy
- Focus Expanded access; Therapeutic Use
- Sponsors Biogen
- 01 Apr 2021 Status changed from recruiting to completed.
- 17 Aug 2020 trail has been completed in Germany as per Germany record
- 29 Aug 2018 Results published in the Neurology